SecBot SecBot
SECBOTREPLAY Home › Report › MGNX

MGNX · MacroGenics announced that the FDA has lifted the partial clinical hold…

MACROGENICS INC · 8-K filed Apr 8, 2026 at 16:41 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 8, 2026 at 16:41 ET

MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, for gynecologic cancers. The company plans to resume enrollment and provide a mid-year program update.

  • FDA removed partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
  • Study evaluates lorigerlimab in patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer
  • To date, 41 patients have been dosed in the LINNET study
  • Company plans to resume enrollment and provide mid-year 2026 update

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access